﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Tabriz University of Medical Sciences</PublisherName>
      <JournalTitle>Advanced Pharmaceutical Bulletin</JournalTitle>
      <Issn>2228-5881</Issn>
      <Volume>14</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2024</Year>
        <Month>10</Month>
        <DAY>10</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Dual-stage Acting Dendrimeric Nanoparticle for Deepened Chemotherapeutic Drug Delivery to Tumor Cells</ArticleTitle>
    <FirstPage>634</FirstPage>
    <LastPage>645</LastPage>
    <ELocationID EIdType="doi">10.34172/apb.2024.054</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mohammad</FirstName>
        <LastName>Shahpouri</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-2272-9121</Identifier>
      </Author>
      <Author>
        <FirstName>Mohammad Amin</FirstName>
        <LastName>Adili-Aghdam</LastName>
      </Author>
      <Author>
        <FirstName>Hossein</FirstName>
        <LastName>Mahmudi</LastName>
      </Author>
      <Author>
        <FirstName>Saeedeh</FirstName>
        <LastName>Ghiasvand</LastName>
      </Author>
      <Author>
        <FirstName>Hamed</FirstName>
        <LastName>Dadashi</LastName>
      </Author>
      <Author>
        <FirstName>Aysan</FirstName>
        <LastName>Salemi</LastName>
      </Author>
      <Author>
        <FirstName>Sajjad</FirstName>
        <LastName>Alimohammadvand</LastName>
      </Author>
      <Author>
        <FirstName>Leila</FirstName>
        <LastName>Roshangar</LastName>
      </Author>
      <Author>
        <FirstName>Abolfazl</FirstName>
        <LastName>Barzegari</LastName>
      </Author>
      <Author>
        <FirstName>Mehdi</FirstName>
        <LastName>Jaymand</LastName>
      </Author>
      <Author>
        <FirstName>Rana</FirstName>
        <LastName>Jahanban-Esfahlan</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-5119-252X</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/apb.2024.054</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2023</Year>
        <Month>11</Month>
        <Day>18</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2024</Year>
        <Month>06</Month>
        <Day>26</Day>
      </PubDate>
    </History>
    <Abstract>Purpose: We report on the design of hypoxia-induced dual-stage acting dendrimeric nanoparticles (NPs) for selective delivery of two chemotherapeutic model drugs doxorubicin (DOX) and tirapazamin (TPZ) for deepened drug delivery into hypoxic tumors in vitro. Methods: PAMAM G5 dendrimers were crosslinked with a hypoxic azo linker, attached to a mPEG to form a detachable corona on the dendrimer surface (PAP NPs). NPs were characterized by Zeta sizer, transmission electron microscope (TEM), Fourier transforms infrared (FTIR) and drug release kinetics. The anti-cancer performance of PAPs was evaluated by numerous tests in 2D and 3D cultured MDA-MB-231 breast cancer cells. Results: MTT assay showed a significant difference between PAP and PAMAMG5 in terms of biocompatibility, and the effect of PAP@DOX was significantly greater than free DOX in hypoxic conditions. The results of DAPI and Annexin V-FITC/PI cell staining also confirmed uniform drug penetration as validated by induction of 90% cell apoptosis in spheroids and a high level of PAP@DOX-induced ROS generation under hypoxia conditions. Mechanistically, PAP@DOX significantly reduced the expression of mTOR, and Notch1, while the expression of Bax and Caspase3 was considerably unregulated, compared to the controls. Importantly, hypoxia-responsive disintegration and hypoxia-induced activation of HAP drug were synergized to promote deep and homogenous HAP distribution in whole microtumor regions to efficiently eliminate residual tumor cells. Conclusion: Our results indicate the safety and high therapeutic potential of PAP system for targeted drug delivery of chemotherapeutics in particular HAPs which show maximum anti-cancer activity against hypoxic solid tumors.</Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hypoxia</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dual-stage acting</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Dendrimeric NPs</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Deep penetration</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Drug delivery</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Residual tumor cells</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>